Am J Psychiatry 155:660-665, May 1998
© 1998 American Psychiatric Association
Cardiovascular Effects of Fluoxetine in Depressed Patients With Heart Disease
Steven P. Roose, M.D.,
Alexander H. Glassman, M.D.,
Evelyn Attia, M.D.,
Sally Woodring, R.N., M.A.,
Elsa-Grace V. Giardina, M.D., and
J. Thomas Bigger, Jr., M.D.
OBJECTIVE: The purpose of this study was to determine the cardiovascular effects of fluoxetine in depressed patients with cardiac disease. METHOD: Twenty-seven depressed patients (26% of whom were female and whose average age was 73 years) who had congestive heart failure, conduction disease, and/or ventricular arrhythmia were studied in an open medication trial of fluoxetine, up to 60 mg/day, for 7 weeks. The main outcome measures were heart rate and rhythm measured by 24-hour ECG recordings, ejection fraction determined by radionuclide angiography, cardiac conduction intervals, and blood pressure. Baseline values were compared with those at weeks 2 and 7 of fluoxetine treatment. In 60 comparable patients, values of these same cardiovascular measures at baseline and after 3 weeks of treatment with a tricyclic antidepressant, nortriptyline, were also examined. RESULTS: Fluoxetine induced a statistically significant 6% decrease in heart rate, a 2% increase in supine systolic pressure, and a 7% increase in ejection fraction. There was no effect on cardiac conduction, ventricular arrhythmia, or orthostatic blood pressure. Overall, 4% of the fluoxetine patients had an adverse cardiovascular effect. In contrast, nortriptyline treatment caused a significant increase in heart rate and orthostatic hypotension, and 20% of the nortriptyline-treated patients had an adverse cardiovascular effect. CONCLUSIONS: In depressed patients with heart disease, fluoxetine treatment was not associated with the cardiovascular effects documented for the tricyclic antidepressants or with significant adverse cardiac events. However, limited conclusions about fluoxetine's cardiovascular effects and safety can be drawn from this study of only 27 patients monitored for 7 weeks.
This article has been cited by other articles:
|
|
|
|
 
B. Wann, T. Bah, S Kaloustian, M Boucher, A. Dufort, N Le Marec, R Godbout, and G Rousseau
Behavioural signs of depression and apoptosis in the limbic system following myocardial infarction: effects of sertraline
J Psychopharmacol,
June 1, 2009;
23(4):
451 - 459.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Sala, M. Lazzaretti, G. De Vidovich, E. Caverzasi, F. Barale, G. d'Allio, and P. Brambilla
Electrophysiological changes of cardiac function during antidepressant treatment
Therapeutic Advances in Cardiovascular Disease,
February 1, 2009;
3(1):
29 - 43.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. L. Rollman, B. H. Belnap, M. S. LeMenager, S. Mazumdar, H. C. Schulberg, and C. F. Reynolds III
The Bypassing the Blues Treatment Protocol: Stepped Collaborative Care for Treating Post-CABG Depression
Psychosom Med,
February 1, 2009;
71(2):
217 - 230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C.T.F. Alves, J. Rays, R. M.S. Telles, R. F. Junior, M. Wajngarten, B. W. Romano, C. Watanabe, and G. F. Busatto
Effects of Antidepressant Treatment on Cognitive Performance in Elderly Subjects With Heart Failure and Comorbid Major Depression: An Exploratory Study
Psychosomatics,
February 1, 2007;
48(1):
22 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Salzman
A 60-Year-Old Woman Who Has Felt Sad for Much of Her Life
JAMA,
January 18, 2006;
295(3):
318 - 323.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Dubnov, R Fogelman, and P Merlob
Prolonged QT interval in an infant of a fluoxetine treated mother
Arch. Dis. Child.,
September 1, 2005;
90(9):
972 - 973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Schulman, P. R. Muskin, and P. A. Shapiro
Psychiatry and Cardiovascular Disease
Focus,
April 1, 2005;
3(2):
208 - 224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Moffitt and A. K. Johnson
Short-term fluoxetine treatment enhances baroreflex control of sympathetic nervous system activity after hindlimb unloading
Am J Physiol Regulatory Integrative Comp Physiol,
March 1, 2004;
286(3):
R584 - R590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. O'Brien and F. Oyebode
Psychotropic medication and the heart
Adv. Psychiatr. Treat.,
November 1, 2003;
9(6):
414 - 423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. L. Serebruany, A. H. Glassman, A. I. Malinin, C. B. Nemeroff, D. L. Musselman, L. T. van Zyl, M. S. Finkel, K. R. R. Krishnan, M. Gaffney, W. Harrison, et al.
Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy
Circulation,
August 26, 2003;
108(8):
939 - 944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Borowicz Jr., R. Royall, M. Grega, O. Selnes, C. Lyketsos, and G. McKhann
Depression and Cardiac Morbidity 5 Years After Coronary Artery Bypass Surgery
Psychosomatics,
December 1, 2002;
43(6):
464 - 471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn
The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels
J. Pharmacol. Exp. Ther.,
February 1, 2002;
300(2):
543 - 548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Nelson and J. R. Abu-Shanab
Management of Depression in Patients with Comorbid Cardiovascular Disease
Journal of Pharmacy Practice,
December 1, 2001;
14(6):
526 - 539.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. H. Sauer, J. A. Berlin, and S. E. Kimmel
Selective Serotonin Reuptake Inhibitors and Myocardial Infarction
Circulation,
October 16, 2001;
104(16):
1894 - 1898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Roose, A. H. Glassman, and S. N. Seidman
Relationship Between Depression and Other Medical Illnesses
JAMA,
October 10, 2001;
286(14):
1687 - 1690.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Varriale
Fluoxetine (Prozac) as a Cause of QT Prolongation
Arch Intern Med,
February 26, 2001;
161(4):
612 - 612.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. M. H. Strik, A. Honig, R. Lousberg, A. H. P. Lousberg, E. C. Cheriex, H. G. Tuynman-Qua, P. M. J. C. Kuijpers, H. J. J. Wellens, and H. M. Van Praag
Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial
Psychosom Med,
December 1, 2000;
62(6):
783 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Januzzi Jr, T. A. Stern, R. C. Pasternak, and R. W. DeSanctis
The Influence of Anxiety and Depression on Outcomes of Patients With Coronary Artery Disease
Arch Intern Med,
July 10, 2000;
160(13):
1913 - 1921.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F CREED
The importance of depression following myocardial infarction
Heart,
October 1, 1999;
82(4):
406 - 408.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Nelson, J. S. Kennedy, B. G. Pollock, F. Laghrissi-Thode, M. Narayan, M. S. Nobler, D. W. Robin, I. Gergel, J. McCafferty, and S. Roose
Treatment of Major Depression With Nortriptyline and Paroxetine in Patients With Ischemic Heart Disease
Am J Psychiatry,
July 1, 1999;
156(7):
1024 - 1028.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Fluoxetine in Depressed Cardiac Patients
Journal Watch Psychiatry,
July 1, 1998;
1998(701):
19 - 19.
[Full Text]
|
|
|
|
|
|
|
Fluoxetine in Depressed Cardiac Patients
Journal Watch (General),
May 26, 1998;
1998(526):
4 - 4.
[Full Text]
|
|
|
|
|
|
|
S. P. Roose, F. Laghrissi-Thode, J. S. Kennedy, J. C. Nelson, J. T. Bigger Jr, B. G. Pollock, A. Gaffney, M. Narayan, M. S. Finkel, J. McCafferty, et al.
Comparison of Paroxetine and Nortriptyline in Depressed Patients With Ischemic Heart Disease
JAMA,
January 28, 1998;
279(4):
287 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
